Glaukos Launches Epioxa HD/Epioxa for Keratoconus Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy GKOS?
Glaukos announced the commercial availability of Epioxa HD/Epioxa, an advancement in corneal cross-linking for the treatment of keratoconus. Epioxa is now commercially available for ordering directly from Glaukos or through its specialty pharmaceutical distribution network.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GKOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GKOS
Wall Street analysts forecast GKOS stock price to rise
13 Analyst Rating
12 Buy
0 Hold
1 Sell
Strong Buy
Current: 107.660
Low
72.00
Averages
127.08
High
165.00
Current: 107.660
Low
72.00
Averages
127.08
High
165.00
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Epioxa™ HD: First Incision-Free Drug Therapy for Keratoconus Approved by FDA
- Innovative Drug Launch: Glaukos announces the commercial availability of Epioxa™ HD as the first FDA-approved incision-free therapy for keratoconus, representing a significant breakthrough in treatment standards that is expected to greatly enhance patient experience and recovery times.
- Patient Support Programs: The company plans to increase investments in patient awareness, education, and access, launching multiple support initiatives including a co-pay assistance program and a patient assistance program aimed at addressing the longstanding issues of underdiagnosis and undertreatment in the keratoconus patient community.
- Significant Clinical Outcomes: Epioxa reduces pain associated with traditional epithelial removal through its enriched oxygen and light mechanism, providing a more comfortable treatment experience while ensuring clinically meaningful outcomes, delivering exceptional value to patients and the healthcare system.
- Substantial Market Potential: With the launch of Epioxa, Glaukos anticipates attracting more attention from keratoconus patients, increasing market share, and driving continued growth in the ophthalmic treatment sector through innovative technologies.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
Glaukos Reports Mixed Q4 Results with Analyst Revisions
- Quarterly Performance: Glaukos reported a Q4 loss of $0.28 per share, missing the analyst consensus of a $0.20 loss, indicating challenges in profitability that may affect investor confidence.
- Sales Beat Expectations: The company achieved quarterly sales of $143.1 million, surpassing the analyst estimate of $136.396 million, suggesting strong product demand that could lay the groundwork for future growth.
- Future Sales Guidance: Glaukos affirmed its FY2026 sales guidance of $600 million to $620 million, demonstrating confidence in future market prospects despite current losses.
- Analyst Rating Revisions: Needham analyst raised Glaukos' price target from $125 to $127, while Wells Fargo increased its target from $122 to $135, reflecting market recognition of the company's long-term potential.
See More
Glaukos Corporation Reports Record Q4 2025 Earnings and Strong 2026 Guidance
- Record Sales Performance: Glaukos Corporation achieved consolidated net sales of $143.1 million in Q4 2025, reflecting a 36% year-over-year increase, with full-year sales reaching $507.4 million, up 32% from 2024, indicating robust growth in the ophthalmic market.
- iDose TR Driving Growth: The iDose TR product generated approximately $45 million in sales during the fourth quarter, with expectations for a 30% year-over-year growth in the U.S. glaucoma market in 2026, highlighting its rapid market acceptance and significant future potential.
- Optimistic Outlook for Epioxa: The newly approved Epioxa therapy for keratoconus has garnered positive interest from the physician community, suggesting it may establish a new standard of care and drive market share growth in the corneal health segment.
- Ongoing Investment and Strategic Planning: The company reaffirmed its 2026 net sales guidance range of $600 million to $620 million, emphasizing a continued balance between capital investments and revenues to achieve cash flow breakeven, ensuring sustainable long-term growth.
See More
Glaukos Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Report: Glaukos reported a Q4 non-GAAP EPS of -$0.28, missing expectations by $0.08, indicating challenges in profitability despite revenue growth.
- Revenue Growth: The company achieved Q4 revenue of $143.1 million, a 35.6% year-over-year increase, exceeding market expectations by $6.08 million, reflecting strong product demand and expanding market share.
- Market Reaction: Despite the EPS miss, Glaukos's stock price rose, indicating investor optimism regarding the company's revenue growth and future potential.
- Future Outlook: With the FDA's approval of the iDose TR labeling update, Glaukos is positioned to enhance its competitive edge, driving future sales growth and improving profitability.
See More
Glaukos Set to Announce Q4 Earnings Expectations
- Earnings Announcement Date: Glaukos (GKOS) is set to announce its Q4 2023 earnings on February 16 after market close, with a consensus EPS estimate of -$0.20, reflecting a 50% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $137.03 million, representing a 29.9% year-over-year increase, which highlights positive trends in market demand and product sales growth, potentially laying a solid foundation for future performance.
- Historical Performance Review: Over the past two years, Glaukos has beaten EPS estimates 50% of the time and has exceeded revenue estimates 100% of the time, demonstrating stability in financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 5 downward revisions, while revenue estimates experienced 7 upward revisions with no downward adjustments, reflecting analysts' mixed views on the company's future performance and optimism regarding revenue growth.
See More
Epioxa™ HD: First Incision-Free Drug Therapy for Keratoconus Approved by FDA
- Innovative Drug Launch: Glaukos announces the commercial availability of Epioxa™ HD as the first FDA-approved incision-free therapy for keratoconus, representing a significant breakthrough in treatment standards that is expected to greatly enhance patient experience and recovery times.
- Patient Support Programs: The company plans to increase investments in patient awareness, education, and access, launching multiple support initiatives including a co-pay assistance program and a patient assistance program aimed at addressing the longstanding issues of underdiagnosis and undertreatment in the keratoconus patient community.
- Significant Clinical Outcomes: Epioxa reduces pain associated with traditional epithelial removal through its enriched oxygen and light mechanism, providing a more comfortable treatment experience while ensuring clinically meaningful outcomes, delivering exceptional value to patients and the healthcare system.
- Substantial Market Potential: With the launch of Epioxa, Glaukos anticipates attracting more attention from keratoconus patients, increasing market share, and driving continued growth in the ophthalmic treatment sector through innovative technologies.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
Glaukos Reports Mixed Q4 Results with Analyst Revisions
- Quarterly Performance: Glaukos reported a Q4 loss of $0.28 per share, missing the analyst consensus of a $0.20 loss, indicating challenges in profitability that may affect investor confidence.
- Sales Beat Expectations: The company achieved quarterly sales of $143.1 million, surpassing the analyst estimate of $136.396 million, suggesting strong product demand that could lay the groundwork for future growth.
- Future Sales Guidance: Glaukos affirmed its FY2026 sales guidance of $600 million to $620 million, demonstrating confidence in future market prospects despite current losses.
- Analyst Rating Revisions: Needham analyst raised Glaukos' price target from $125 to $127, while Wells Fargo increased its target from $122 to $135, reflecting market recognition of the company's long-term potential.
See More
Glaukos Corporation Reports Record Q4 2025 Earnings and Strong 2026 Guidance
- Record Sales Performance: Glaukos Corporation achieved consolidated net sales of $143.1 million in Q4 2025, reflecting a 36% year-over-year increase, with full-year sales reaching $507.4 million, up 32% from 2024, indicating robust growth in the ophthalmic market.
- iDose TR Driving Growth: The iDose TR product generated approximately $45 million in sales during the fourth quarter, with expectations for a 30% year-over-year growth in the U.S. glaucoma market in 2026, highlighting its rapid market acceptance and significant future potential.
- Optimistic Outlook for Epioxa: The newly approved Epioxa therapy for keratoconus has garnered positive interest from the physician community, suggesting it may establish a new standard of care and drive market share growth in the corneal health segment.
- Ongoing Investment and Strategic Planning: The company reaffirmed its 2026 net sales guidance range of $600 million to $620 million, emphasizing a continued balance between capital investments and revenues to achieve cash flow breakeven, ensuring sustainable long-term growth.
See More
Glaukos Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Report: Glaukos reported a Q4 non-GAAP EPS of -$0.28, missing expectations by $0.08, indicating challenges in profitability despite revenue growth.
- Revenue Growth: The company achieved Q4 revenue of $143.1 million, a 35.6% year-over-year increase, exceeding market expectations by $6.08 million, reflecting strong product demand and expanding market share.
- Market Reaction: Despite the EPS miss, Glaukos's stock price rose, indicating investor optimism regarding the company's revenue growth and future potential.
- Future Outlook: With the FDA's approval of the iDose TR labeling update, Glaukos is positioned to enhance its competitive edge, driving future sales growth and improving profitability.
See More
Glaukos Set to Announce Q4 Earnings Expectations
- Earnings Announcement Date: Glaukos (GKOS) is set to announce its Q4 2023 earnings on February 16 after market close, with a consensus EPS estimate of -$0.20, reflecting a 50% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $137.03 million, representing a 29.9% year-over-year increase, which highlights positive trends in market demand and product sales growth, potentially laying a solid foundation for future performance.
- Historical Performance Review: Over the past two years, Glaukos has beaten EPS estimates 50% of the time and has exceeded revenue estimates 100% of the time, demonstrating stability in financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 5 downward revisions, while revenue estimates experienced 7 upward revisions with no downward adjustments, reflecting analysts' mixed views on the company's future performance and optimism regarding revenue growth.
See More
